GENEVA -- The interleukin-23 inhibitor guselkumab generates the same impressive improvement in skin disease in
psoriatic arthritis patients as has been seen in psoriasis without joint disease, Alexa B.
M2 EQUITYBITES-December 18, 2017-Pfizer receives US FDA approval for
psoriatic arthritis drugs Xeljanz and Xeljanz XR
M2 PHARMA-December 18, 2017-Pfizer receives US FDA approval for
psoriatic arthritis drugs Xeljanz and Xeljanz XR
announced today that the United States Food and Drug Administration (FDA) has approved XELJANZ 5 mg twice daily (BID) and XELJANZ XR (tofacitinib) extended release 11 mg once daily (QD) for the treatment of adult patients with active
psoriatic arthritis (PsA) who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).
Hyperuricemia is a common finding in
psoriatic patients.
Psoriatic arthritis raises the risk of type 2 diabetes, and the risk correlates with higher disease activity, according to Canadian investigators.
Dr Takiddin says it is important to promote better understanding of the various types of psoriasis, including
psoriatic arthritis, among both the general public and healthcare professionals.
Psoriatic onycho-pachydermo-periostitis (POPP) was initially described by Fournie B in 1989.
USPRwire, Sun Jan 17 2016]
Psoriatic arthritis is a chronic inflammatory disease that affects the distal joints in the body and may also affect the back and sacroiliac joints of the pelvis.
Some cases of
psoriatic arthritis (PsA) cannot be explicitly diagnosed especially when the skin and nail lesions present years after the joint disease or are absent.
Psoriatic arthritis is a member of the spondyloarthropathy family and may be defined as an inflammatory arthropathy associated with psoriasis, usually negative for rheumatoid factor.
which can lead to more serious symptoms and damaging comorbidities, including
psoriatic arthritis (PsA), cardiovascular disease, and inflammatory bowel disease (IBD).
